fbpx
Menu

Zogenix Provides Corporate Update and Reports Third Quarter Financial Results

Share

Reported positive top-line results from second pivotal Phase 3 trial of FINTEPLA (ZX008) in patients with Dravet syndrome, Study 1504 rare central nervous system (CNS) disorders…

[Read on via official release]

Source: US SEC
View full document:
EX-991_of_8-K_for_ZOGENIX_INC__8-K-11-08-2018